Dogwood Therapeutics (DWTX) to Release Earnings on Thursday

Dogwood Therapeutics (NASDAQ:DWTX) is expected to be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Dogwood Therapeutics to post earnings of ($1.23) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:30 AM ET.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its earnings results on Wednesday, August 13th. The company reported ($1.99) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.73). On average, analysts expect Dogwood Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Dogwood Therapeutics Stock Performance

DWTX opened at $6.17 on Thursday. Dogwood Therapeutics has a twelve month low of $1.62 and a twelve month high of $29.28. The firm has a market cap of $14.13 million, a P/E ratio of -0.33 and a beta of 1.89. The business has a 50 day moving average price of $5.55 and a 200 day moving average price of $5.15.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on DWTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dogwood Therapeutics in a report on Wednesday, October 8th. HC Wainwright upped their price target on Dogwood Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, September 30th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.